Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Telios Pharma, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed/refractory CLL or relapsed/refractory SLL (Arms 1, 2, 5, and 7)
Treatment naïve CLL or SLL (Arm 3, 4, and 6)
ECOG performance status of ≤ 2
Adequate hematologic, hepatic, and renal functions
You may not be if
Prior treatment with any BTK or PI3K inhibitors
History of major organ transplant
Women who are pregnant or breastfeeding
Clareo Health | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects
